Publications
3 shownDurable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
Purpose Nivolumab provides clinical benefit (objective response rate [ORR], 31%; 95% CI, 20.8 to 42.9; disease control rate, 69%; 12-month overall survival [OS], 73%) in previou...
Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Colon Cancer focuses on systemic therapy options for the treatment of metastatic colo...
Frequent Co-Authors
Researcher Info
- h-index
- 3
- Publications
- 3
- Citations
- 3,866
- Institution
- The University of Texas MD Anderson Cancer Center
External Links
Identifiers
- ORCID
- 0000-0001-5377-135X
Impact Metrics
h-index
3
h-index: Number of publications with at least h citations each.